Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

nger patients. In the Phase 1 trial, voreloxin was administered on a weekly or twice-weekly schedule and patient demographics were similar between the two treatment schedules. Six patients, including four age 60 or older and two younger than age 60, achieved complete remission (CR) or complete remission without platelet recovery (CRp) or complete remission with incomplete recovery of hematopoeitic elements (CRi) when voreloxin was administered at doses of 50 mg/m2 or greater weekly or 40 mg/m2 twice-weekly. Duration of complete remissions (CR or CRp) was reported. Remissions of up to seven months have been observed thus far, with two patients undergoing reinduction with voreloxin following relapse.

Sixty-eight patients were evaluable for safety, with 42 patients ranging in age from 60-85 years old and 26 patients age 21-59 years. Voreloxin was generally well tolerated in both the older and younger patient subgroups with similar incidence of Grade 3-4 adverse events. The dose-limiting toxicity was reversible oral mucositis, and a maximum-tolerated dose of 72 mg/m2 once-weekly and 40 mg/m2 twice-weekly was established. Researchers also reported that voreloxin pharmacokinetics were not influenced by age.

"AML is primarily a disease of the elderly and the medical need for new agents that can be tolerated by older patients remains unmet. Results from our comparative analysis demonstrate that voreloxin is generally well tolerated and achieves anti-leukemic activity among older, advanced AML patients, supporting our strategy for progressing the clinical development of voreloxin in this indication," said Glenn Michelson, M.D., Vice President, Clinical Strategy at Sunesis. "Sunesis recently initiated the Phase 2 REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) clinical trial to evaluate voreloxin in newly diagnosed AML in elderly patients. We hope to present initial data from the REVEAL-1 trial later this year."

Preliminary Data from Phase 1b S
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Hologic, Inc. (NASDAQ: HOLX ... President and Chief Executive Officer, will preside over the ... the first day of Breast Cancer Awareness Month. In ... focused on the important benefits of Hologic,s 3D Mammography ... as clinically superior to traditional mammography. ...
(Date:9/30/2014)... 30, 2014 This study provides an ... informatics solutions including nuclear imaging informatics, PET imaging ... study assesses the size of the market based ... and projects future growth based on the current ... taking place in the broader markets for imaging ...
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... OrthoWorx, the newly formed industry, community and education initiative to ... is working to connect the orthopedics capital of the world ... , In a September report, Warsaw, ... overview, analysis and blueprint for future industry and community growth, ...
... , , KNOXVILLE, Tenn., Dec. 15 Medical researchers ... their revolutionary new technology for a simple blood test to ... of its pre-clinical trials for the ColoMarker(TM) assay, EDP has ... of its use. Via an inexpensive blood test, ColoMarker(TM) ...
Cached Medicine Technology:OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 2OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 3Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Farmington ... including a redefined mission and visual identity helping ... of partnering with them to create greater benefit ... brand that focuses on empowering customers to better ... , The crown jewel of the rebrand is ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... 2014 Anti Aging Clinic (AntiAgingClinic.ca), the ... destination of choice, is announcing a discounted cost on ... December. , “We’re doing this because we want to ... top skin clinic in Toronto,” says Dr. Brian Sieber, ... at Anti Aging Clinic, including laser facials, genesis laser ...
(Date:10/1/2014)... Nordic Naturals is kicking off a ... The campaign—“Buy One Bottle. Help Two Heroes.”—will raise ... nonprofit organization that helps rebuild the lives of ... would otherwise face euthanasia. From October through December ... donations of Nordic Naturals omega-3s to veterans and ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... Bullying may contribute to a drop in high school students, ... high achievers, a new study has found. Researchers compared ... U.S. high schools. The students were asked if they experienced ... not bullied, kids who were bullied experienced a 0.049 drop ...
... Victims of bullying often suffer academically, and this ... students, according to new research to be presented at ... "Although academic achievement is largely influenced by ... the experience of being bullied also influences students, grades," ...
... MONDAY, Aug. 22 (HealthDay News) -- The risk of ... more than doubled since the early 1990s and it ... used to be, U.S. researchers report. They analyzed ... that infections related to cardiac electrophysiological devices (CIEDs) increased ...
... , A new University of Missouri study finds that ... "For years, popular psychologists have insisted that boys and ... held back by fears of embarrassment or appearing weak," said ... MU College of Arts and Science. "However, when we ...
... , MONDAY, Aug. 22 (HealthDay News) -- ... a new study indicates. Pilots, doctors and others in ... fatigued people who work as a team have better problem-solving ... They asked 171 army officer cadets, aged 18 to 24, ...
... of nurses who work in outpatient chemotherapy infusion centers reported ... drugs they deliver, according to a new study from the ... 1,339 oncology nurses from one state who did not work ... delivered in outpatient settings, largely by nurses. Results appear online ...
Cached Medicine News:Health News:Grades May Suffer When Teens Get Bullied 2Health News:Bullying victims often suffer academically, particularly high achieving blacks and Latinos 2Health News:Males believe discussing problems is a waste of time, MU study shows 2Health News:17 percent of cancer nurses unintentionally exposed to chemotherapy, U-M study finds 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: